<DOC>
	<DOCNO>NCT00961480</DOCNO>
	<brief_summary>A three part study demonstrate bioequivalence single dose Final Market Image ( FMI ) sitagliptin/metformin 50/500 , 50/850 50/1000 mg Fixed-Dose Combination ( FDC ) tablet co-administration corresponding dose sitagliptin metformin individual tablet . Subject participate one part , receive treatment A B ( Part I ) , Treatment C D ( Part II ) Treatment E F ( Part III ) .</brief_summary>
	<brief_title>A Study Demonstrate Bioequivalence Sitagliptin/Metformin Combination Tablets Co-administration Sitagliptin Metformin Individual Tablets ( 0431A-095 )</brief_title>
	<detailed_description />
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Female subject reproductive potential test negative pregnancy agree use appropriate contraception Subject good health nonsmoker Subject history neoplastic disease ( cancer ) , stroke , chronic seizure , major neurological disorder Subject history clinically significant endocrine , gastrointestinal , cardiovascular , hematological , hepatic , immunological , renal , respiratory , genitourinary abnormality diseases Subject nursing mother Subject consume excessive amount alcohol caffeine Subject donate blood , surgery participate another clinical study within past 4 week</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>